Literature DB >> 24147489

Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound.

Kyoung Doo Song1, Min Woo Lee, Hyunchul Rhim, Dong Ik Cha, Yousun Chong, Hyo K Lim.   

Abstract

OBJECTIVE: The objective of our study was to assess whether fusion imaging of conventional ultrasound and liver CT or MR images can improve the conspicuity of lesions and feasibility of percutaneous radiofrequency ablation (RFA) for the treatment of hepatocellular carcinomas (HCCs) not visible on ultrasound. Whether peritumoral anatomic landmarks can be used for the placement of an electrode in HCCs not visible on ultrasound even after image fusion was also evaluated.
MATERIALS AND METHODS: Planning ultrasound for percutaneous RFA was performed using conventional ultrasound first and then using fusion imaging later during the same session. The visibility of HCCs and feasibility of RFA on conventional ultrasound and on fusion imaging were assessed. We evaluated how many HCCs initially not visible on conventional ultrasound could be visualized and ablated after applying the fusion imaging technique. One hundred twenty HCCs not visible on conventional ultrasound in 96 patients were included.
RESULTS: When fusion imaging was applied, 38 of the 120 (31.7%) HCCs that were initially not visible could be seen and RFA was feasible. Among the remaining 82 HCCs still not visible after image fusion, 26 (31.7%) were ablated under the guidance of fusion imaging the technique based on peritumoral anatomic landmarks. Overall, 64 of 120 (53.3%) HCCs (59.4%, 57 of 96 patients) not visible on conventional ultrasound could be ablated under the guidance of the fusion imaging technique.
CONCLUSION: Fusion imaging can improve the conspicuity of HCCs and the feasibility of percutaneous RFA of HCCs not visible on conventional ultrasound. Peritumoral anatomic landmarks can be used for electrode placement in HCCs that are still not visible even after image fusion.

Entities:  

Mesh:

Year:  2013        PMID: 24147489     DOI: 10.2214/AJR.13.10532

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  23 in total

1.  Clinical experience with cone-beam CT navigation for tumor ablation.

Authors:  Nadine Abi-Jaoudeh; Aradhana M Venkatesan; William Van der Sterren; Alessandro Radaelli; Bart Carelsen; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2015-02       Impact factor: 3.464

2.  Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang; Dan Wang
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

3.  Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.

Authors:  Yasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
Journal:  Eur Radiol       Date:  2017-12-01       Impact factor: 5.315

Review 4.  Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  J Med Ultrason (2001)       Date:  2020-02-08       Impact factor: 1.314

5.  Thermal ablation with fusion imaging guidance of hepatocellular carcinoma without conspicuity on conventional or contrast-enhanced US: surrounding anatomical landmarks matter.

Authors:  Marco Calandri; Valeria Ruggeri; Patrizia Carucci; Stefano Mirabella; Andrea Veltri; Paolo Fonio; Carlo Gazzera
Journal:  Radiol Med       Date:  2019-07-03       Impact factor: 3.469

6.  Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Dan Wang; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

Review 7.  Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim
Journal:  Liver Cancer       Date:  2015-07-17       Impact factor: 11.740

8.  Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.

Authors:  Jun Gon Kim; Sung Ki Cho; Dongho Hyun; Sung Wook Shin; Kwang Bo Park; Hong Suk Park; Sung Wook Choo; Young Soo Do; Sook-Young Woo; Sun-Young Baek
Journal:  Abdom Radiol (NY)       Date:  2021-09-28

9.  Assessing the value of volume navigation during ultrasound-guided radiofrequency- and microwave-ablations of liver lesions.

Authors:  Philippa Meershoek; Nynke S van den Berg; Jacob Lutjeboer; Mark C Burgmans; Rutger W van der Meer; Catharina S P van Rijswijk; Matthias N van Oosterom; Arian R van Erkel; Fijs W B van Leeuwen
Journal:  Eur J Radiol Open       Date:  2021-07-08

Review 10.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.